This week on Contemporary OB/GYN®: Jan. 3 to Jan. 7
A look at what's coming to Contemporary OB/GYN® this week
FDA authorizes Pfizer, Merck COVID-19 antiviral pills
The moves bring two new weapons to the toolbox for physicians fighting the pandemic.
Top 3 challenges of 2022
Each year, the Medical Economics® team surveys their audience to find out what big challenges practitioners faced. By far, the top answer was “administrative burdens,” including staffing, prior authorizations and electronic health records (EHRs). Let's take a closer look at what these burdens entail to help physicians get ready for whatever challenges 2022 will bring.
Hair dyes, bleach, relaxers, and mousse associated with lower levels of sex steroid hormones
A new Rutgers study indicates a connection between specific personal care products and lower levels of sex steroid hormones, which have a critical role in maintaining pregnancy and fetal development.
Coming soon
Pap Talk: Season 4
With the new year, Contemporary OB/GYN® kicks off a new season of its Pap Talk podcast on Wednesday, Jan. 5.
Coming soon
Community births, and risks, increase with COVID-19 pandemic
New research in the American Journal of Obstetrics and Gynecology showed a rise in community births during the COVID-19 pandemic, as many women thought a hospital delivery to be more dangerous. The data told a different story.
Coming soon
Major congenital malformations not linked to first trimester tetracycline use
November 20th 2024A large population-based study found that first-trimester tetracycline exposure does not elevate the risk of major congenital malformations, though specific risks for nervous system and eye anomalies warrant further research.
Read More
IUD placement within 48 hours nonsuperior vs 2 to 4 weeks after abortion
November 19th 2024A study reveals no significant difference in 6-month intrauterine device use between placements within 48 hours or 2 to 4 weeks after a second-trimester abortion, though earlier placement carries a higher expulsion risk.
Read More
